Slovakia-based contract development and manufacturing organisation (CDMO) Saneca Pharmaceuticals has sold registration dossiers for more than 20 pharmaceutical products to Switzerland-headquartered Xantis Pharma as part of an exclusive agreement.
As part of the deal, Hlohovec-based Saneca Pharma will hold an exclusive five-year contract manufacturing agreement with Xantis Pharma.
Saneca Pharma develops and manufactures a pharmaceutical dosage forms, including solids, liquids, gels and creams. The firm also has a portfolio of synthetic APIs, and opiate APIs from plant biomass.
The Xantis Pharma portfolio consists of a range of molecules for treating conditions in the fields of cardiology, gastroenterology, men’s health and pain management, while also building on the Sanorin brand for cough and cold and nasal decongestants.
The 20 products will be marketed by Xantis Pharma throughout Central and Eastern Europe, where the company has a growing presence.
Saneca Pharma will continue to act as Xantis Pharma’s agent for out-licensing opportunities for the dossiers outside these regions.
We are looking forward to working together to expand the reach of these products in Europe
Anthony Sheehan, CEO at Saneca Pharma, said: 'We have an established relationship with Xantis Pharma for manufacturing pharmaceutical products based on Xantis’s own registration dossiers.
'With the purchase of Saneca Pharma’s dossiers, the relationship has now evolved to another level, so we are looking forward to working together to expand the reach of these products in Europe.
'The partnership combines Xantis Pharma’s market knowledge and access to central and eastern Europe markets with Saneca Pharma’s technical agility and cost effective development and manufacturing expertise. In the coming months, we expect to see more rapid growth of existing product lines and speedier market entry for those in our pipeline.'
Grigory Chudakov, Chief Commercial Officer at Xantis Pharma, said: 'By combining our strong market presence in Central and Eastern Europe with Saneca Pharma’s strengths in drug development and manufacturing, we are confident that we can expand the reach of the 20 pharmaceutical products that have transferred to our portfolio.'
The two firms have also committed to working together to develop nine new products in the next three years. Saneca Pharma will use its expertise in formulation development and regulatory support, while Xantis Pharma will promote the new offerings to the market.
